Clinical trial
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best…
NCT00113763 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00113763 |
|---|---|
| Title | Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer |
| Official title | An Open-label, Randomized, Phase 3 Clinical Trial of ABX-EGF Plus Best Supportive Care Versus Best Supportive Care in Subjects With Metastatic Colorectal Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Metastases |
| Intervention type | Drug, Other |
| Interventions | Best supportive care, Panitumumab |
| Enrollment | 463 |
| Start date | Jan 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | Jun 1, 2009 |
| First posted | Jun 13, 2005 |
| Last update posted | Nov 7, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: